INSILICO (03696) and Boreas announce a strategic alliance to advance AI-driven drug development.

INSILICO (03696) announced that it has entered into a multi-faceted strategic alliance with the leading pharmaceutical manufacturing company, Boray Pharmaceuticals Co., Ltd (Boray; Taiwan Stock Exchange: 6472; OTCQX: BORAY). This alliance will establish a broad and multi-faceted cooperation framework, with specific details of the cooperation to be further discussed and finalized by both parties. If fully implemented, the potential value of the proposed collaboration is expected to exceed $2.5 billion. The proposed collaboration under this alliance will be agreed upon by INSILICO and Boray through subsequent negotiations and the signing of a final agreement. It aims to integrate INSILICO's Pharma.AI platform's technological advantages in target discovery, chemical generation, and molecular optimization, as well as Boray's professional capabilities in global drug development, manufacturing, quality management, and commercialization. By connecting AI-enabled research and development systems with automated development, manufacturing, and quality execution processes, INSILICO and Boray aim to jointly pioneer a new generation of drug innovation models, bridging the gap between design and development of novel molecules, manufacturing, and the delivery of drugs to patients with unmet medical needs.